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abstractThis 2019 focused update to the American Heart Association pediatric
advanced life support guidelines follows the 2018 and 2019 systematic
reviews performed by the Pediatric Life Support Task Force of the
International Liaison Committee on Resuscitation. It aligns with the
continuous evidence review process of the International Liaison Committee
on Resuscitation, with updates published when the International Liaison
Committee on Resuscitation completes a literature review based on new
published evidence. This update provides the evidence review and treatment
recommendations for advanced airway management in pediatric cardiac
arrest, extracorporeal cardiopulmonary resuscitation in pediatric cardiac
arrest, and pediatric targeted temperature management during post–cardiac
arrest care. The writing group analyzed the systematic reviews and the
original research published for each of these topics. For airway management,
the writing group concluded that it is reasonable to continue bag-mask
ventilation (versus attempting an advanced airway such as endotracheal
intubation) in patients with out-of-hospital cardiac arrest. When
extracorporeal membrane oxygenation protocols and teams are readily
available, extracorporeal cardiopulmonary resuscitation should be considered
for patients with cardiac diagnoses and in-hospital cardiac arrest. Finally, it
is reasonable to use targeted temperature management of 32°C to 34°C
followed by 36°C to 37.5°C, or to use targeted temperature management of
36°C to 37.5°C, for pediatric patients who remain comatose after resuscitation
from out-of-hospital cardiac arrest or in-hospital cardiac arrest.
This 2019 focused update to the
American Heart Association (AHA)
pediatric advanced life support (PALS)
guidelines for cardiopulmonary
resuscitation (CPR) and emergency
cardiovascular care (ECC) is based on 3
systematic reviews1–3 and the resulting
“2019 International Consensus on
Cardiopulmonary Resuscitation
and Emergency Cardiovascular
Care Science With Treatment
Recommendations” (CoSTR) from
the Pediatric Life Support Task Force
of the International Liaison Committee
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on Resuscitation (ILCOR).4 This
pediatric life support task force
CoSTR addressed 3 topics: advanced
airway management in pediatric
cardiac arrest, extracorporeal CPR
(ECPR) in pediatric cardiac arrest,
and pediatric targeted temperature
management (TTM) during
post–cardiac arrest care. The draft
pediatric CoSTRs were posted online
for public comment,5–7 and
a summary document containing the
final CoSTR wording has been
published simultaneously with this
focused update.4
AHA guidelines for CPR and ECC are
developed in concert with ILCOR’s
systematic review process. In 2015,
the ILCOR evidence evaluation
process and the AHA development of
guidelines updates transitioned to
a continuous, simultaneous process,
with systematic reviews performed as
new published evidence warrants or
when the ILCOR Pediatric Life
Support Task Force prioritizes
a topic. The AHA science experts
review the new evidence and update
the AHA’s guidelines for CPR and ECC
as needed, typically on an annual
basis. A description of the evidence
review process is available in the
2017 ILCOR summary.8
The ILCOR systematic review
process uses the Grading of
Recommendations Assessment,
Development, and Evaluation
methodology and its associated
nomenclature to determine the
strength of recommendation and
certainty of effect for the CoSTR. The
expert writing group for this 2019
PALS focused update analyzed and
discussed the original studies and
carefully considered the ILCOR
Pediatric Life Support Task Force
consensus recommendations4 in light
of the structure and resources of
the out-of-hospital and in-hospital
resuscitation systems and providers
who use AHA guidelines. In
addition, the writing group came to
a consensus about the Classes of
Recommendation and Levels of
Evidence according to the
nomenclature developed by the
American College of Cardiology/AHA
recommendations for developing
clinical practice guidelines (Table)9
by using the process detailed in
the “2015 American Heart
Association Guidelines Update for
Cardiopulmonary Resuscitation and
Emergency Cardiovascular Care.”10
It is importantto note that this 2019
focused update to the AHA PALS
guidelines re-evaluates only the
recommendations for the use of
advanced airway management during
cardiac arrest, the use of ECPR during
cardiac arrest, and the use of TTM
after cardiac arrest. All other
recommendations and algorithms
published in “Part 12: Pediatric
Advanced Life Support” in the 2015
AHA guidelines update11 and “Part
14: Pediatric Advanced Life Support”




remain the official recommendations
of the AHA ECC Science
Subcommittee and writing groups.
The other recommendations
contained in the 2017 and 2018
focused updates to the AHA’s
pediatric basic and advanced life
support guidelines continue to apply
to care delivered to pediatric patients
in cardiac arrest.13,14
ADVANCED AIRWAY INTERVENTIONS IN
PEDIATRIC CARDIAC ARREST
Most pediatric cardiac arrests are
triggered by respiratory
deterioration.15,16 As a result, airway
management and ventilation
management are fundamental
components of PALS. A number of
options exist for airway management
in pediatric cardiac arrest. Although
the majority of pediatric patients can
be successfully ventilated with bag-
mask ventilation (BMV), this method
requires interruptions in chest
compressions and is associated with
risk of aspiration and barotrauma.
Although endotracheal intubation can
partially mitigate the risk of
aspiration and enables delivery of
uninterrupted chest compressions, it
requires specialized equipment and
skilled providers. Pediatric airway
anatomy differs from that of adults,
so tracheal intubation may be more
difficult for healthcare professionals
who do not routinely intubate
pediatric patients. A supraglottic
airway (SGA) such as the laryngeal
mask airway may be easier to place
than an endotracheal tube, but it does
not provide a definitive airway and
does not mitigate the risk of
aspiration.
Evidence Summary—Updated 2019
The 2019 ILCOR Pediatric Life
Support Task Force and the AHA
pediatric writing group reviewed 14
studies of advanced airway
interventions in pediatric patients
with cardiac arrest. This included
a clinical trial,17 3 propensity-
adjusted studies,18–20 8 retrospective
cohort studies,21–28 and 2
retrospective studies.29,30 The review
included evidence for the use of an
advanced airway (endotracheal
intubation or SGA) versus BMV only.4
This topic was last reviewed in
2010,12 and the previous review did
not directly compare outcomes
associated with these 3 modalities.
Endotracheal Intubation Compared With
BMV
All 14 studies in the systematic
review examined the outcomes of
endotracheal intubation versus BMV
during pediatric cardiac arrest. The
only clinical trial in the review
randomized pediatric patients with
out-of-hospital cardiac arrest (OHCA)
to either BMV alone or BMV followed
by endotracheal intubation.17 There
was no significant difference between
the groups in favorable neurologic
outcome or survival to hospital
discharge.
Two propensity-adjusted studies
were included in the review. In
a database study from the Get With
The Guidelines–Resuscitation
registry, endotracheal intubation
during in-hospital cardiac arrest
(IHCA) was associated with
decreased survival to hospital
discharge.18 A review from an
American cardiac arrest registry,
CARES (American Cardiac Arrest
Registry to Enhance Survival), of
pediatric patients with OHCA
comparing outcomes of patients
treated with BMV and those treated
with endotracheal intubation found
an association between BMV and
more than double the rate of survival
to hospital discharge (odds ratio, 2.56
[95% CI, 1.69–3.85]).19
SGA Placement Compared With BMV
Alone
Four observational studies were
identified in the 2019 ILCOR
systematic review of pediatric SGA
versus BMV. All were focused on
patients with OHCA. Two presented
propensity-adjusted cohort data,19,20
and 2 provided simple observational
data.26,28 In the 2 propensity-adjusted
reviews, from the All-Japan Utstein
Registry20 and CARES,19 comparing
outcomes of SGA versus BMV,
there was no association between
the use of SGA and increased
favorable neurologic outcome.
In 2 non–propensity-matched
observational studies comparing the
use of SGA with BMV,26,28 the SGA was
associated with a significant increase
in survival to hospital discharge and
return of spontaneous circulation.
SGA Placement Compared With
Endotracheal Intubation
Four observational studies (2 were
propensity adjusted) also compared
endotracheal intubation with SGA in
pediatric patients with OHCA. When
compared, neither SGA nor
endotracheal intubation was
associated with a significant increase
or decrease in favorable neurologic
outcome or survival to hospital
discharge.19,20,26,28 Similarly, when
SGA and endotracheal intubation
were compared, neither was
associated with significant
improvement in survival to hospital
admission. However, 1 cohort study




The pediatric ILCOR CoSTR authors
attempted to conduct a subgroup
analysis to compare outcomes of
pediatric IHCA and OHCA, as well as
traumatic versus medical causes of
arrest. Outcomes from IHCA and
OHCA were similar. However, very
few studies focused on IHCA; these
included 1 propensity-matched
cohort study18 and 2 other cohort
studies.23,27 Outcomes of traumatic
and nontraumatic arrest could not be
compared because published studies
included only a small number of
patients identified as having
traumatic arrest.
Recommendation—Updated 2019
1. BMV is reasonable compared
with advanced airway
interventions (endotracheal
intubation or SGA) in the
management of children during
cardiac arrest in the out-of-
hospital setting (Class 2a; Level
of Evidence C-LD).
We cannot make a recommendation
for or against the use of an advanced
airway for IHCA management. In
addition, no recommendation can be
made about which advanced airway
intervention is superior in either
OHCA or IHCA.
Discussion
The use of advanced airways in
pediatric cardiac arrest was last
reviewed by ILCOR in 2010, with the
following recommendation: “In the
prehospital setting it is reasonable to
ventilate and oxygenate infants and
children with a bag-mask device,
especially if transport time is short
(Class IIa, LOE [Level of Evidence]
B).”12 This 2019 focused update
reaffirms the 2010 recommendation
with no significant changes. In
addition, we highlight the evidence
associated with the use of specific
types of airway intervention,
endotracheal intubation and SGAs,
comparing their effects with those of
BMV. The evidence for this
recommendation was largely from
observational studies, so reported
findings must be interpreted as
associated with, rather than caused
by, the intervention. However, the
writing group agreed that a Class 2a
recommendation was appropriate.
When used by providers with proper
experience and training, BMV was not
associated with inferior outcomes
compared with endotracheal
intubation or SGA; thus, BMV is
a reasonable alternative to these
advanced airways, which may require
more specific training or equipment.
During OHCA, transport time,
provider skill level and experience,
and equipment availability should be
considered in the selection of the
most appropriate airway
intervention. If BMV is ineffective
despite appropriate optimization,
more advanced airway interventions
should be considered.
The writing group determined that
there was insufficient evidence to
make any recommendation about
advanced airway management for
IHCA and could not determine
whether either endotracheal
intubation or SGA was superior in
either setting.
ECPR FOR IHCA
The use of extracorporeal membrane
oxygenation (ECMO) as a form of
mechanical circulatory rescue for
failed conventional CPR (ie, ECPR)
has gained popularity since its first
use as a form of postcardiotomy
rescue in children after surgery for
congenital heart disease.31,32 ECPR is
defined as the rapid deployment of
venoarterial ECMO during active CPR
or for patients with intermittent
return of spontaneous circulation.
ECPR is a resource-intense, complex
multidisciplinary therapy that
traditionally has been limited to large
academic medical centers with
providers who have expertise in the
management of children with cardiac
disease. Judicious use of ECPR for
specialized patient populations and
within dedicated and highly practiced
environments has proved successful,
especially for IHCA with reversible
causes.33 ECPR use rates have
increased, with single-center reports
in both adults and children
suggesting that application of this
therapy across broader patient
populations may improve survival
after both OHCA and IHCA.34–36
Evidence Summary—Updated 2019
The ILCOR Pediatric Life Support
Task Force and the AHA pediatric
writing group reviewed 3 studies on
the use of ECPR in pediatric cardiac
arrest. The first study was
a retrospective review (2000–2008)
of the Get With The
Guidelines–Resuscitation registry of
pediatric patients with IHCA after
cardiac surgery.37 On adjusted
multivariate analysis, the use of ECPR
was associated with higher rates of
survival to hospital discharge than
conventional CPR. A second review of
the same database used a propensity
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analysis to examine the association of
ECPR with favorable neurologic
outcome in patients with IHCA of any
origin.38 During an 11-year period
(January 2000–December 2011),
3756 patients were enrolled, with
591 receiving ECPR. Compared with
conventional CPR, the use of ECPR
was associated with higher favorable
neurologic outcome at hospital
discharge (odds ratio, 1.78 [95% CI,
1.31–2.41]).
A third study was a single-center
retrospective review of patients with
congenital heart disease who
experienced cardiac arrest during
cardiac catheterization.39 During
a total of 7289 cardiac catheterization
procedures, 70 infants and children
had cardiac arrest; of these, 18 (26%)
received ECPR. The use of ECPR was
associated with worse survival to
hospital discharge compared with
conventional CPR, although there was
no adjustment for potential
confounding variables.
The pediatric ILCOR systematic
review and CoSTR4,6 found no
published studies reporting the
outcomes after the application of
ECPR for pediatric OHCA.
Recommendation—Updated 2019
1. ECPR may be considered for
pediatric patients with cardiac
diagnoses who have IHCA in
settings with existing ECMO
protocols, expertise, and
equipment (Class 2b; Level of
Evidence C-LD).
There is insufficient evidence to
recommend for or against the use of
ECPR for pediatric patients
experiencing OHCA or for pediatric
patients with noncardiac disease
experiencing IHCA refractory to
conventional CPR.
Discussion
The 2015 AHA PALS guidelines
suggested that ECPR “be considered
for pediatric patients with cardiac
diagnoses who have IHCA in settings












































































































































































































































































































































































































































































































































































































































































expertise, and equipment (Class IIb,
LOE [Level of Evidence] C-LD).”11
There were no prospective
comparative analyses comparing
survival and neurologic outcomes
between conventional CPR and ECPR.
This is not surprising given the
potential ethical and logistical
challenges in recruiting children for
a prospective randomized trial during
a cardiac arrest. However, data from
large multicenter registry and
retrospective propensity score
analyses in child and adult
populations suggest that ECPR may
provide a significant survival benefit
when used for refractory cardiac
arrest.38,40,41 Presumably, without
ECPR, many of these patients would
have died as a result of failed
resuscitation attempts.
Current survival to hospital discharge
rates for critically ill children
experiencing IHCA resuscitated with
conventional CPR range from 29% to
44%.42,43 In contrast, recent ECPR
studies of pediatric IHCA have
reported survival to hospital
discharge rates for mixed cardiac and
noncardiac ICU populations as high as
48%.32,44,45 Additional analyses
reported that ECPR in the cardiac ICU
was associated with higher survival
to hospital discharge rates in patients
with surgical cardiac disease
compared with patients in the general
ICU setting (73% versus 42%,
respectively).46–48 Our understanding
of neurologic function after
resuscitation with ECPR consists of
single-center follow-up analyses49,50
and the results of a randomized
prospective trial of therapeutic
hypothermia after IHCA.51
There is insufficient information about
neurologic complications and outcomes
(ie, hemorrhagic/ischemic stroke,
seizure) associated with the use of
ECPR in infants and children. In
a multicenter randomized trial of
therapeutic hypothermia after IHCA,
only 30.5% of patients who received
ECPR for IHCA had good
neurobehavioral outcomes at
12 months of age.51 In patients who
received ECPR, therapeutic
hypothermia, compared with
normothermia, tended to be associated
with lower survival with good
neurobehavioral outcome at 1 year.51
Single-center analyses lack
consistency in reported measures of
neurologic function/status yet
demonstrate favorable neurologic
outcomes for the majority of
survivors at follow-up (median range,
25–52 months).49,50 Post–cardiac
arrest care for patients undergoing
ECPR should include ongoing
surveillance for neurologic injury
through the end of the ECMO course.
POST–CARDIAC ARREST TTM
TTM refers to continuous
maintenance of patient temperature
within a narrowly prescribed range.
In initial studies of temperature
management after cardiac arrest in
adults52 and after hypoxic-ischemic




management that did not include
fever prevention. In these early
studies, fever in the control group
may have contributed to worse
outcomes and to the comparatively
higher survival reported in the group
treated with hypothermia. More
recent studies compared what was
described as therapeutic hypothermia
(32°C–34°C) with controlled
normothermia (36°C–37.5°C), with
fever actively prevented.16,54 These
treatment modalities are now
referred to as TTM 32°C to 34°C and
TTM 36°C to 37.5°C, respectively.
Therapeutic hypothermia treats
reperfusion syndrome after cardiac
arrest by decreasing metabolic
demand, reducing free radical
production, and decreasing
apoptosis.55 It is not clear whether
TTM to different temperature ranges
has the same impact.
Evidence Summary—Updated 2019
The 2019 ILCOR pediatric CoSTR
summarized the evidence supporting
the use of TTM (32°C–34°C) after
IHCA or OHCA in infants, children,
and adolescents ,18 years of age.4,7
This pediatric review was triggered
by the publication of the results of the
THAPCA-IH trial (Therapeutic
Hypothermia After Pediatric Cardiac
Arrest In-Hospital), a randomized
controlled trial of TTM 32°C to 34°C
versus TTM 36°C to 37.5°C for
IHCA.54 Unlike previous ILCOR
reviews and several earlier AHA PALS
guidelines, the ILCOR pediatric
CoSTR4 and this 2019 PALS focused
update are based only on evidence
from pediatric studies; this update
did not consider evidence
extrapolated from adult studies. The
writing group agreed that pediatric
patients receiving TTM after cardiac
arrest differ substantially from adult
patients because infants and children
have different causes of cardiac
arrest, initial arrest rhythms, and
techniques and equipment used for
TTM, as well as differences in
post–cardiac arrest care, compared
with adults.
The THAPCA-IH trial was a large,
multi-institutional, prospective,
randomized controlled study of
infants and children 2 days to
18 years of age. Methods and
outcomes analyzed were identical to
the 2015 THAPCA-OH trial
(Therapeutic Hypothermia After
Pediatric Cardiac Arrest Out-of-
Hospital).16 Both THAPCA studies
evaluated the association between
temperature targets and outcomes in
children who received chest
compressions for at least 2 minutes,
were comatose (motor Glasgow Coma
Scale score ,5), and were dependent
on mechanical ventilation after return
of spontaneous circulation; both
studies used the same protocol.16,54
The only difference between the
studies was the location of the arrest
of the enrolled patients. The primary
outcome evaluated for both trials was
favorable neurobehavioral outcome at
1 year, with secondary outcomes of
survival at 1 year and change in
neurobehavioral outcome. In both
studies, temperature targets were
actively maintained for 120 hours
with the use of anteriorly and
posteriorly placed automated cooling
blankets. Temperature was
continuously and centrally
monitored. Patients in the TTM 32°C
to 34°C group were cooled to a core
temperature of 33°C (range, 32°C–34°
C) with neuromuscular blockade and
sedation for the first 48 hours. They
were then rewarmed over a minimum
of 16 hours and actively maintained
at 36.8°C (range, 36°C–37.5°C) for the
remainder of the study. Patients in the
TTM 36°C to 37.5°C cohort received
identical care except for a targeted
temperature of 36.8°C (range, 36°
C–37.5°C) for the entire 5-day
intervention period.16,54
The THAPCA-IH trial was halted for
futility after enrollment of 59% of
targeted patients because the primary
outcome (favorable neurobehavioral
outcome at 1 year) did not differ
significantly between the TTM 32°C
to 34°C (36%, 48 of 133) and TTM
36°C to 37.5°C (39%, 48 of 124;
relative risk, 0.92% [95% CI,
0.67–1.27]; P = .63) groups.
Secondary outcomes, including
a change in neurobehavioral outcome
score by at least 1 SD from prearrest
baseline at 1 year (30% versus 29%;
P = .70), survival at 28 days (63%
versus 59%; P = .40), and survival at
1 year (49% versus 46%; P = .56), did
not differ between TTM groups. There
were no significant differences
between the temperature groups in
the frequency of adverse events,
including infection, need for
transfusion, and serious arrhythmias
within the first 7 days.54
The THAPCA-OH trial analyzed data
from 260 patients. There was no
significant difference in the primary
outcome between patients treated
with TTM 32°C to 34°C and those
treated with TTM 36°C to 37.5°C
(20% versus 12%; relative risk, 1.59
[95% CI, 0.89–2.85]). There were also
no differences in secondary
outcomes, including change in
neurobehavioral scores from baseline,
survival at 28 days, or survival at
1 year.16
Recommendations—Updated 2019
1. Continuous measurement of
core temperature during TTM is
recommended (Class 1; Level of
Evidence B-NR).
2. For infants and children
between 24 hours and 18 years
of age who remain comatose
after OHCA or IHCA, it is
reasonable to use either TTM
32°C to 34°C followed by TTM
36°C to 37.5°C or to use
TTM 36°C to 37.5°C (Class 2a;
Level of Evidence B-NR).
There is insufficient evidence to
support a recommendation about
treatment duration. The THAPCA
(Therapeutic Hypothermia After
Pediatric Cardiac Arrest) trials used
2 days of TTM 32°C to 34°C followed
by 3 days of TTM 36°C to 37.5°C or
used 5 days of TTM 36°C to 37.5°C.
Discussion
Since publication of the 2015 PALS
guidelines, an additional randomized
controlled trial of TTM of comatose
children after IHCA has been
published.54 This in-hospital study,
from the same investigational team
and with the same treatment protocol
as the out-of-hospital study,16
compared post–cardiac arrest TTM
32°C to 34°C with TTM 36°C to 37.5°C.
Together, these trials form the basis
of the current guidelines. Although
several pediatric observational
studies were also included in the
ILCOR evidence review,7 the
observational studies had differing
inclusion and exclusion criteria and
varying protocols for temperature
management, duration of TTM, and
definitions of harm.56–59 In addition,
although there are several
randomized controlled trials of TTM
within the adult population, the ILCOR
Pediatric Life Support Task Force and
this writing group placed a higher
value on pediatric data because the
adult studies include patients with
arrest causes, disease states, and
outcomes that differ from those of
children and thus would provide only
indirect evidence.
Although there were no significant
differences in outcomes between the
2 TTM groups in the THAPCA trials
(ie, therapeutic hypothermia versus
therapeutic normothermia),
hypothermia has been shown to be
advantageous in animal models and
neonatal hypoxic injury and in
mediating the adverse effects of the
post–cardiac arrest syndrome. Given
the severity of neurologic injury that
many children demonstrate after
resuscitation from cardiac arrest,
cardiac arrest poses a substantial
public health burden, representing
large numbers of years lost, which
makes potential interventions to
improve neurologic injury and
survival a critical priority.
Although interpretation of many
studies of pediatric patients
resuscitated from IHCA or OHCA is
challenged by low-quality evidence in
heterogeneous populations, most
observational studies have yielded
similar findings.56–59 These studies
used different control groups, arrest
locations, age groups, causes of
arrest, duration of TTM, and type of
follow-up. Despite 1 small
observational study of TTM in OHCA
survivors demonstrating statistical
improvement in neurologic
recovery59 and an observational
study of IHCA demonstrating worse
neurologic outcomes and survival
after TTM,56 the majority of studies
have demonstrated no differences in
ICU duration of stay, neurologic
outcomes, and mortality with the use
of therapeutic hypothermia versus
controlled normothermia.
Both THAPCA trials16,54 and 2
observational studies60,61 used active
normothermia to maintain
temperature below the febrile range.
The other 7 observational
studies56–59,62–64 analyzed in the
systematic review3 did not control
temperature in the control group;
thus, there was a risk of fever that
could have contributed to worse
outcomes in the control group. This
lack of temperature regulation in the
control groups is a key limitation and
a potential source of bias in these
studies. Fever is common after
a hypoxic-ischemic event such as
cardiac arrest and has been shown
from registry data to be associated
with worse outcomes after cardiac
arrest.65 The negative results of
recent TTM trials may be explained
by the active maintenance of
normothermia in control patients
rather than a true noneffect of
hypothermia. The early trials
of hypothermia in both neonates
and adults did not prevent fever,
whereas later trials did.53,66,67
A more recent TTM trial in
neonates receiving ECMO used
normothermic temperatures in
the control group and did not
demonstrate differences in
outcomes or adverse effects.68
Whether using TTM 32°C to 34°C
followed by TTM 36°C to 37.5°C
or using TTM 36°C to 37.5°C for
infants and children who remain
comatose after return of spontaneous
circulation, the avoidance of fever
is paramount.
Although these treatment
recommendations apply to both
OHCA and IHCA, it is important to
recognize that outcomes of OHCA and
IHCA differ in several key
determinants. Response intervals are
inherently longer for OHCA, as are the
times to initiation of CPR, airway
management, pharmacological
therapies, and defibrillation. The
presence of comorbidities, initial
rhythms, and arrest causes all differ
between children with OHCA and
those with IHCA. However, because
the conclusions of the 2 THAPCA
trials16,54 were the same, we have
made a merged recommendation for
both OHCA and IHCA.
The ILCOR pediatric ECPR systematic
review included multiple subgroup
analyses evaluating the critical
outcomes of favorable
neurobehavioral function and
survival at multiple time points.3
These subgroup analyses included
location of arrest (OHCA versus
IHCA), presumed cause of arrest
(cardiac, asphyxial, drowning), and
use of ECMO. Although no subgroup
analysis was found to favor one
treatment over another, the analyses
were limited because only 1
randomized trial exists for each
location, and the small sample sizes
and lack of conformity within the
observational trials prevented the
pooling of data. Subgroup analyses of
adverse events, including infection,
serious bleeding, and recurrent
cardiac arrest, were feasible from
only the 2 randomized controlled
trials. These studies found no
statistical difference in positive
outcomes or complications between
TTM 32°C to 34°C and TTM 36°C to
37.5°C groups in either THAPCA
trial.16,54 Significant limitations
persist even in the randomized trials,
which affects the certainty of any
recommendation about TTM during
post–cardiac arrest care. Patient
recruitment, especially in the
randomized trials, occurred over
many years, during which
recommendations for CPR changed,
including the recent changes to put
greater emphasis on CPR quality. The
exclusion criteria were extensive and
may have excluded some patients
who might have benefitted from TTM.
Finally, and significantly, across the
sites, there was no consistent use of
a post–cardiac arrest care bundle
such as identifying and supporting
optimal blood pressure, metabolic or
oxygen/ventilation targets, and
methods of supportive care.
In the randomized trials,16,54 the
duration of TTM was 120 hours (5
days). In the observational trials,
the duration of hypothermia
varied from 24 to 72 hours.56,58–64
Similarly, the duration of the
rewarming period varied. Because
no randomized trial tested the
duration of TTM, the writing group
felt that there was insufficient
evidence to make a specific
recommendation on this important
aspect of the therapy.
Given the uncertainty of the effect
of TTM, limitations of the data
analysis, and lack of demonstrable
harm, we agree that it is reasonable
for clinicians to use TTM to 32°C
to 34°C followed by TTM 36°C to
37.5°C or to use TTM 36°C to
37.5°C. Clinicians should
consistently implement the
strategy that can most safely
be performed for a specific
patient in a specific clinical
environment. Regardless of
strategy, providers should strive to
prevent fever .37.5°C.
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